newsOrphan Drug Designation has been granted to the CT053 anti-BCMA…
2 September 2019 | By Rachael Harper (European Pharmaceutical Review)
Orphan Drug Designation has been granted to the CT053 anti-BCMA CAR-T programme for multiple myeloma treatment.